Europe is in many ways considered to be the ‘home turf’ of Oxymat A/S and although the Denmark based PSA manufacturer is the largest of its kind in Europe – the company is finding growth in the Middle East.
This fact is due to the European medical market still only slowly opening up to PSA generated oxygen.
Even though the introduction of the Oxygen 93 Monograph in 2011 made it possible to deliver 93% PSA produced oxygen to European hospital patients, it seems the EU market is still trying its way around this oxygen supply source – and this, even though PSA produced oxygen is in full compliance with strict European standards.
... to continue reading you must be subscribed
